Razzouk 2006.

Methods	randomized controlled trial, placebo‐controlled
Participants	n = 126, solid tumors, Hodgkin disease, Non‐Hodgkin lymphoma (patients excluded from the present meta‐analysis), acute lymphocytic leukemia (patients excluded from the present meta‐analysis); concomitant treatment: chemotherapy
Interventions	drug = Epoetin alpha dose = 600 IU/kg iv weekly hb‐target = 13‐15 g/dL (age > 12 years), 13‐14 g/dL (age <12 years) planned ESA duration = 16 weeks
Outcomes	Primary: QoL; secondary: Hb, transfusion
Notes	study number = 80515
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Low risk	computer generated
Allocation concealment?	Low risk	central randomization and coded drug packs of identical appearance